PhaseBio Pharmaceuticals Inc. (PHAS) PT Lowered to $16 at Needham & Company
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St up after tech selloff as yields retreat; Moderna surges
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Francisco Partners to acquire Weave Communications for $650M
PhaseBio Reports First-Quarter 2021 Financial Results and Recent Business Highlights
May 13, 2021 4:00 PM EDTContinued enrollment progress in Phase 3 REVERSE-IT clinical trial for Bentracimab
Signed commercial supply agreement with BioVectra to support development and commercialization of lead product candidate bentracimab
Completed underwritten public offering of common stock yielding $60.1 million in net proceeds
MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)-- PhaseBio Pharmaceuticals, Inc. (Nasdaq:... More
